Search
Publications
Paroxysmal Cold Hemoglobinuria: Diagnosis from the Blood Smear. [20-Mar-2022]
Radhakrishnan K. ; Downie P.A.; Earley C.M.Pearson syndrome. [20-Apr-2023]
Tedjaseputra A. ; Radhakrishnan K. ; Martin M.; Downie P. ; Stergiotis M.; Bain B.J.Vaccine beliefs, adverse effects, and quality of life in patients with cancer undergoing routine COVID-19 vaccination. [8-Aug-2024]
Body A. ; Donoghoe M.; Lal L.; Wakefield C.; Ahern E.S.; Anazodo A.; Bolanos N.A.F.; Padhye B.; Downie P. ; Opat S. ; Hamad N.; Leahy M.F.; Milch V.; Segelov E.
Abstract
in an infection- and vaccine-naive cancer population. Patients with current or recent solid or hematological malignancy, aged five and over, had serial assessments prior to and following multiple SARS-CoV-2 vaccinations. Electronic surveys were administered
Uridine treatment normalizes the congenital dyserythropoietic anemia type II-like hematological phenotype in a patient with homozygous mutation in the CAD gene. [21-Dec-2020]
Radhakrishnan K. ; Iolascon A.; Fahey M. ; Russo R.; Marra R.; Andolfo I.; Manna F.; De Rosa G.; Rosato B.E.Two cases of refractory IgG4-related disease successfully treated with tocilizumab. [29-Jun-2022]
Ong J.; Brown S.; Gilbertson M. ; Grigoriadis G. ; Simpson I.; Vilcassim S.; Low M. ; Fedele P. ; Motorna O.; Roberts L. ; Gingold M. ; Gregory G.Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer. [12-Dec-2024]
Body A. ; Lal L.; Srihari S.; MacIntyre C.R.; Buttery J. ; Ahern E.S.; Opat S. ; Leahy M.F.; Hamad N.; Milch V.; Turville S.; Smith C.; Lineburg K.; Naing Z.; Rawlinson W.; Segelov E.
Abstract
RNA vaccine (BNT162b2 = 347; mRNA-1273 = 1) or viral vector vaccine (ChadOx1-S = 43) for initial two-dose course, plus up to three additional doses. Median age was 58 years (range: 20-85); 60 % were female; 35 % had haematological malignancy, 2/395 (0.5 %) had
Benchmarking Paediatric Sickle Cell Care in Australia. [24-Nov-2023]
Greenway A.L.; Kaplan Z.; Barbaro P.; Carter T.; Teo J.; Pal M.
Abstract
for curative therapies (bone marrow transplantation). Aim(s): To survey aspects of health care service delivery for paediatric SCD at six specialist centres in Australia. Method(s): Lead clinicians at the six centres were surveyed to determine: basic
Consensus guidelines for improving patients' understanding of invasive fungal disease and related risk prevention in the haematology/oncology setting, 2021. [25-Dec-2021]
Fernando S.S.; Paige E.K.; Dendle C. ; Weinkove R.; Kong D.C.M.; Omond P.; Routledge D.J.; Szer J.; Blyth C.C.
Abstract
and New Zealand consensus guidelines for the management of IFD and antifungal use in the haematology/oncology setting outlines the key information needs of patients and their carers/families. It specifically addresses risk factor reduction, antifungal
Trends in childhood oncology admissions to ICUs in Australia and New Zealand. [11-Dec-2023]
Wraight T.I.; Namachivayam S.P.; Maiden M.J.; Erickson S.J.; Oberender F.; Singh P.; Gard J.; Ganeshalingham A.; Millar J.
Abstract
.1-2.5%) in 2017-2018 (p trend = 0.02). The greatest reduction in mortality seen in hematological cancers and in nonelective admissions. Mechanical ventilation rates were unchanged from 2003 to 2018, while the use of high-flow nasal prong oxygen increased
Critical review of current clinical practice guidelines for antifungal therapy in paediatric haematology and oncology. [2-Oct-2017]
Kotecha R.S.; Haeusler G.M.; McMullan B.J.; Slavin M.A.; Clark J.E.; Blyth C.C.Discover
By type
- 96 Publications